Topics:

FDA Approves Torisel for Renal Cell Carcinoma

FDA Approves Torisel for Renal Cell Carcinoma

ROCKVILLE, Maryland—FDA has approved Wyeth's Torisel (temsirolimus) for the treatment of advanced renal cell carcinoma, based on a study showing prolonged survival with Torisel as a single agent vs interferon alfa. Median overall survival was 10.9 months for Torisel patients vs 7.3 months for interferon patients. Progression-free survival increased from 3.1 months with interferon to 5.5 months with Torisel. The combination of Torisel and interferon did not result in a significant increase in overall survival, compared with interferon alone. Look for a complete report on the approval in the July issue of ONI.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.